Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Amortization - Intangibles (2016 - 2018)

Historic Amortization - Intangibles for Ironwood Pharmaceuticals (IRWD) over the last 3 years, with Q3 2018 value amounting to $1.2 million.

  • Ironwood Pharmaceuticals' Amortization - Intangibles fell 3890.35% to $1.2 million in Q3 2018 from the same period last year, while for Dec 2018 it was $8.1 million, marking a year-over-year increase of 3052.78%. This contributed to the annual value of $8.1 million for FY2018, which is 3052.78% up from last year.
  • Ironwood Pharmaceuticals' Amortization - Intangibles amounted to $1.2 million in Q3 2018, which was down 3890.35% from $3.5 million recorded in Q2 2018.
  • Ironwood Pharmaceuticals' 5-year Amortization - Intangibles high stood at $3.5 million for Q4 2017, and its period low was $420000.0 during Q1 2017.
  • Moreover, its 3-year median value for Amortization - Intangibles was $2.5 million (2016), whereas its average is $2.2 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Amortization - Intangibles tumbled by 6046.95% in 2017 and then surged by 72761.9% in 2018.
  • Over the past 3 years, Ironwood Pharmaceuticals' Amortization - Intangibles (Quarter) stood at $3.3 million in 2016, then grew by 5.33% to $3.5 million in 2017, then plummeted by 66.66% to $1.2 million in 2018.
  • Its Amortization - Intangibles stands at $1.2 million for Q3 2018, versus $3.5 million for Q2 2018 and $3.5 million for Q1 2018.